Harnessing the power of Artificial Intelligence to unlock further potential of known drugs for orphan diseases

We leverage the power of Artificial Intelligence to repurpose drugs for orphan diseases

We are a team of talented scientists with a passion for innovation

Learn about us

STANDARD DRUG DISCOVERY AND DEVELOPMENT

WE CAN REDUCE THOSE NUMBERS TO

OUR APPROACH

PROPRIETARY PIPELINE

PARTNERSHIP

OUR PERFORMANCE INDICATORS

WE COOPERATE WITH

SOM BIOTECH IN THE MEDIA

LATEST NEWS

SOM Biotech signs licensing agreement

SOM Biotech signs licensing agreement with the University of Minnesota

May 17, 2022
SOM Biotech announced that it has signed a licensing agreement with the University of Minnesota. This license agreement follows the completion of research under a sponsored research agreement (SRA) signed in 2019, in which the University of Minnesota conducted a series of in vitro studies on potential pre-clinical product candidates for Duchenne and Becker muscular…
SOM Biotech at Rare Disease Day 2022

Rare Disease Day 2022

February 28, 2022
Today is Rare Disease Day 2022! At SOM Biotech we recognize the importance of raising awareness and progressing scientific research in the field of Rare Diseases. You can see our publications supporting rare Disease Day on LinkedIn and Twitter. Join us and get involved today: https://www.rarediseaseday.org/#.

SOM Biotech signs letter of intent with Megapharm to commercialize SOM3355 in Israel and the Palestinian Authority

December 15, 2021
SOM Biotech (“SOM” or the “Company”), a clinical-stage biopharmaceutical company with a proprietary AI-based drug discovery technology and a focus on neurological orphan diseases, today announces that it has signed a letter of intent with Megapharm Ltd. (“Megapharm”), a leading Israel-based pharmaceutical company, regarding a potential exclusive distribution agreement for the commercialization of SOM3355 to…

SOM Biotech granted Orphan Drug Designation by the FDA for SOM3355

October 18, 2021
SOM3355 has the potential to be an alternative to current VMAT2 inhibitors with a significantly improved side effect profile for the treatment of chorea in Huntington´s disease.  SOM Biotech (“SOM” or the “Company”), a clinical-stage drug discovery and development company focused on orphan diseases of the Central Nervous System, today announces that the U.S. Food…
SOM Biotech presents positive Phase 2a data with SOM3355

SOM Biotech presents positive Phase 2a data with SOM3355 at the 34thECNP Congress 2021

October 4, 2021
Data show SOM3355 reduces chorea in patients with Huntingdon’s Disease and has a good safety profile. SOM3355 discovered through SOM Biotech’s proprietary artificial intelligence-based computational technology SOMAI PRO. SOM Biotech today announces it will be presenting positive Phase 2a data with SOM3355, an oral vesicular monoamine transporter 2 (VMAT2) inhibitor for the symptomatic treatment of…
Artificial Intelligence in Healthcare

SOM Biotech performed a presentation at the University of Barcelona Summer Course dedicated to Rare Diseases

July 28, 2021
SOM Biotech performed a presentation at the University of Barcelona Summer Course dedicated to Rare Diseases. The course was held from the 5th to the 9th of July. Dr. Raúl Insa, CEO of the company, performed the presentation on the topic of drug repurposing for Rare Diseases. The main objective of the course was to…